For
the quarter ending March 2023, consolidated Net sales (including other operating income) of Glaxosmithkline Pharmaceuticals has declined 2.74% to Rs 787.45 crore compared to quarter ended Mar 2022. Operating profit margin has declined from 21.64% to 21.56%, leading to 3.13% decline in operating profit to Rs 169.74 crore. Raw material cost as a % of total sales (net of stock adjustments) decreased from 18.74% to 13.17%. Purchase of finished goods cost rose from 23.29% to 24.88%. Employee cost increased from 17.72% to 20.83%. Other expenses fell from 18.09% to 17.36%. Other income rose 47.44% to Rs 27.66 crore. PBIDT rose 1.76% to Rs 197.4 crore. Provision for interest rose 132.14% to Rs 0.65 crore. Loan funds declined from Rs 20.07 crore as of 31 March 2022 to Rs 15.54 crore as of 31 March 2023. Inventories declined from Rs 534.70 crore as of 31 March 2022 to Rs 459.97 crore as of 31 March 2023. Sundry debtors were lower at Rs 192.38 crore as of 31 March 2023 compared to Rs 205.24 crore as of 31 March 2022. Cash and bank balance declined from Rs 2,484.51 crore as of 31 March 2022 to Rs 1,155.93 crore as of 31 March 2023. Investments rose to Rs 518.29 crore as of 31 March 2023 from Rs 365.59 crore as of 31 March 2022 .
PBDT rose 1.57% to Rs 196.75 crore. Provision for depreciation rose 11.92% to Rs 17.18 crore. Fixed assets declined from Rs 326.65 crore as of 31 March 2022 to Rs 316.18 crore as of 31 March 2023. Intangible assets declined from Rs 34.50 crore to Rs 34.09 crore.
Profit before tax grew 0.68% to Rs 179.57 crore. Share of profit/loss were nil in both the periods. Extraordinary items were decreased to Rs 10.40 crore. PBT after EO decreased 8.60% to Rs 189.97 crore. Provision for tax was expense of Rs 56.54 crore, compared to Rs 262.51 crore. Effective tax rate was 29.76% compared to 126.30%.
Minority interest was nil in both the periods. Net profit was Rs 133.43 crore, compared to loss of Rs 54.66 crore.Equity capital stood at Rs 169.41 crore as of 31 March 2023 to Rs 169.41 crore as of 31 March 2022. Per share face Value remained same at Rs 0.10.
Promoters’ stake was 75.00% as of 31 March 2023 ,compared to 75.00% as of 31 March 2022 .
Full year results analysis.
Net sales (including other operating income) of Glaxosmithkline Pharmaceuticals has declined 0.80% to Rs 3251.72 crore. Operating profit margin has jumped from 23.24% to 24.73%, leading to 5.57% rise in operating profit to Rs 804.29 crore. Raw material cost as a % of total sales (net of stock adjustments) decreased from 18.73% to 13.43%. Purchase of finished goods cost rose from 22.36% to 24.77%. Employee cost decreased from 18.70% to 18.69%. Other expenses rose from 16.85% to 17.83%. Other income rose 32.83% to Rs 100.66 crore. PBIDT rose 8.03% to Rs 904.95 crore. Provision for interest fell 9.50% to Rs 1.81 crore. Loan funds declined from Rs 20.07 crore as of 31 March 2022 to Rs 15.54 crore as of 31 March 2023. Inventories declined from Rs 534.70 crore as of 31 March 2022 to Rs 459.97 crore as of 31 March 2023. Sundry debtors were lower at Rs 192.38 crore as of 31 March 2023 compared to Rs 205.24 crore as of 31 March 2022. Cash and bank balance declined from Rs 2,484.51 crore as of 31 March 2022 to Rs 1,155.93 crore as of 31 March 2023. Investments rose to Rs 518.29 crore as of 31 March 2023 from Rs 365.59 crore as of 31 March 2022 .
PBDT rose 8.08% to Rs 903.14 crore. Provision for depreciation fell 3.55% to Rs 65.77 crore. Fixed assets declined from Rs 326.65 crore as of 31 March 2022 to Rs 316.18 crore as of 31 March 2023. Intangible assets declined from Rs 34.50 crore to Rs 34.09 crore.
Profit before tax grew 9.11% to Rs 837.37 crore. Share of profit/loss were nil in both the periods. Provision for tax was expense of Rs 228.76 crore, compared to Rs 398.28 crore. Effective tax rate was 27.35% compared to 51.12%.
Minority interest was nil in both the periods. Net profit attributable to owners of the company increased 59.58% to Rs 607.64 crore.
Equity capital stood at Rs 169.41 crore as of 31 March 2023 to Rs 169.41 crore as of 31 March 2022. Per share face Value remained same at Rs 0.10.
Promoters’ stake was 75.00% as of 31 March 2023 ,compared to 75.00% as of 31 March 2022 .
Cash flow from operating activities decreased to Rs 484.23 crore for year ended March 2023 from Rs 810.74 crore for year ended March 2022. Cash flow used in acquiring fixed assets during the year ended March 2023 stood at Rs 44.04 crore, compared to Rs 34.64 crore during the year ended March 2022.
Dividend update
Board has recommended a dividend of Rs 32
per equity share on face value of Rs 10 each for the year ended 31 March 2023.